.svg | CAS_number = 50-07-7 | ATC_prefix = L01 | ATC_suffix = DC03 | ATC_supplemental = | PubChem = 5746 | DrugBank = APRD00284 |C = 15 |H = 18 |N = 4 |O = 5 | molecular_weight = 334.327 g/mol | bioavailability = | protein_bound = | metabolism = Hepatic| elimination_half-life = 8-48 min | pregnancy_category = D (Au, U.S.)| legal_status = ℞-only (U.S.), POM (UK)| routes_of_administration = Exclusively intravenous}} The mitomycins are a family of aziridine-containing natural products isolated from Streptomyces lavendulae. One of these compounds, mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity. It is given intravenously to treat upper gastro-intestinal (e.g. esophageal carcinoma) and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage.

External links

• Mitomycin (CancerBACUP)
• Mitomycin (MedlinePlus)
• Mitomycin C from Fermentek, a vendor's product page

References

• Hata, T.; Sano, Y.; Sugawara, R.; Matsumae, A.; Kanamori, K.; Shima, T.; Hoshi, T. J. Antibiot. Ser. A 1956, 9, 141-146.
• Fukuyama, T.; Yang, L. "Total Synthesis of (±)-Mitomycins via Isomitomycin A." J. Am. Chem. Soc. 1987, 109, 7881-7882.
• Mao, Y.; Varoglu, M.; Sherman, D.H. "Molecular characterization and analysis of the biosynthetic cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564." Chemistry & Biology 1999, 6, 251-263.
• Varoglu, M.; Mao, Y.; Sherman, D.H. "Mapping the Biosynthetic Pathway by Functional Analysis of the MitM Aziridine N-Methyltransferase." J. Am. Chem. Soc. 2001, 123, 6712-6713 and references therein.

Chemotherapeutic agents

Mitomycin | マイトマイシンC | Mitomycyna